References
1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5 (4): 536–44. DOI: https://doi.org/10.1038/s41564-020-0695-z
2. WHO. Director-General’s Opening Remarks at the Media Briefing on COVID-19. Geneva, Switzerland: World Health Organization, 2020. URL: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020
3. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). URL: https://coronavirus.jhu.edu/map.html
4. Huang C., Wang Y., Li X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10 223): 497–506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5
5. Li X., Geng M., Peng Y., et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020; 10 (2): 102–8. DOI: https://doi.org/10.1016/j.jpha.2020.03.001
6. Chatterjee S.K., Saha S., Munoz M.N.M. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci. 2020; 7: 196. DOI: https://doi.org/10.3389/fmolb.2020.00196
7. Fagni F., Simon D., Tascilar K., et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol. 2021; 3 (10): 724–36. DOI: https://doi.org/10.1016/S2665-9913(21)00247-2
8. Garcia Garrido H.M., Grobusch M.P., D’Haens G.R.A.M., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2021; 6 (7): 523. DOI: https://doi.org/10.1016/S2468-1253(21)00148-5
9. Najm A., Alunno A., Mariette X., et al. Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. RMD Open. 2021; 7 (1): e001549. DOI: https://doi.org/10.1136/rmdopen-2020-001549
10. Furer V., Rondaan C., Heijstek M., et al. Incidence and prevalence of vaccine preventable infections in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD): a systemic literature review informing the 2019 update of the EULAR recommendations for vaccination in adult patients with AIIRD. RMD Open. 2019; 5 (2): e001041. DOI: https://doi.org/10.1136/rmdopen-2019-001041
11. Mehta B., Pedro S., Ozen G., et al. Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study. RMD Open. 2019; 5 (1): e000935. DOI: https://doi.org/10.1136/rmdopen-2019-000935
12. Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Coronavirus and IBD Reporting Database: Current Data. URL: https://covidibd.org/current-data/
13. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020; 5 (1): 17–30. DOI: https://doi.org/10.1016/S2468-1253(19)30333-4
14. Ahlawat S., Asha, Sharma K.K. Immunological co-ordination between gut and lungs in SARS-CoV-2 infection. Virus Res. 2020l; 286: 198103. DOI: https://doi.org/10.1016/j.virusres.2020.198103
15. Mao R., Qiu Y., He J.S., et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020; 5 (7): 667–78. DOI: https://doi.org/10.1016/S2468-1253(20)30126-6
16. Ungaro R.C., Brenner E.J., Gearry R.B., et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021; 70 (4): 725–32. DOI: https://doi.org/10.1136/gutjnl-2020-322539
17. Bezzio C., Saibeni S., Variola A., et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020; 69 (7): 1213–7. DOI: https://doi.org/10.1136/gutjnl-2020-321411
18. Quartuccio L., Zabotti A., Del Zotto S., et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2018; 15: 87–93. DOI: https://doi.org/10.1016/j.jare.2018.09.003
19. Kumar A., Quraishi M.N., Segal J.P., et al. COVID-19 vaccinations in patients with inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020; 5 (11): 965–6. DOI: https://doi.org/10.1016/S2468-1253(20)30295-8
20. D’Amico F., Rabaud C., Peyrin-Biroulet L., Danese S. SARS-CoV-2 vaccination in IBD: more pros than cons. Nat Rev Gastroenterol Hepatol. 2021; 18 (4): 211–3. DOI: https://doi.org/10.1038/s41575-021-00420-w
21. Alexander J.L., Kennedy N.A., Lees C.W., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021; 6 (3): 218–24. DOI: https://doi.org/10.1016/S2468-1253(21)00024-8
22. Siegel C.A., Melmed G.Y., McGovern D.P.B., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021; 70 (4): 635–40. DOI: https://doi.org/10.1136/gutjnl-2020-324000
23. Ferretti F., Cannatelli R., Benucci M., et al. How to manage COVID-19 vaccination in immune-mediated inflammatory diseases: an expert opinion by IMIDs Study Group. Front Immunol. 2021; 12: 656362. DOI: https://doi.org/10.3389/fimmu.2021.656362
24. Melmed G.Y., Rubin D.T., McGovern D.P.B. Winter is coming! Clinical, immunologic, and practical considerations for vaccinating patients with inflammatory bowel disease during the Coronavirus disease – 2019 pandemic. Gastroenterology. 2021; 160 (3): 639–44. DOI: https://doi.org/10.1053/j.gastro.2020.10.013
25. Priority vaccination of respiratory infections during the SARSCOV-2 pandemic and after its completion. A guide for physicians. In: M.P. Kostinov, A.G. Chuchalin (eds). Moscow: MDV, 2020: 32 p. (in Russian)
26. Kostinov M.P., Svitich O.A., Markelova E.V. Potential COVID-19 immunoprophylaxis in high-risk groups. Temporary allowance for physicians. Moscow: MDV, 2020: 64 p. (in Russian)
27. Guidelines for clinical immunology in respiratory medicine. 2nd ed. In: M.P. Kostinov, A.G. Chuchalin (eds). Moscow: MDV, 2018: 304 p. (in Russian)
28. Kostinov M.P. Vaccination of adults – from strategy to tactics. A guide for physicians. Moscow: MDV, 2020: 248 p. (in Russian)
29. Melmed G.Y., Ippoliti A.F., Papadakis K.A., et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006; 101 (8): 1834–40. DOI: https://doi.org/10.1111/j.1572-0241.2006.00646.x
30. Rahier J.F., Magro F., Abreu C., et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8 (6): 443–68. DOI: https://doi.org/10.1016/j.crohns.2013.12.013
31. Huth K., Benchimol E.I., Aglipay M., Mack D.R. Strategies to improve influenza vaccination in pediatric inflammatory bowel disease through education and access. Inflamm Bowel Dis. 2015; 21 (8): 1761–8. DOI: https://doi.org/10.1097/MIB.0000000000000425
32. Apte M., Reich J., Farraye F.A. Vaccinations for patients with inflammatory bowel disease: an updated review. Pract Gastroenterol. 2018; 42 (12): 64–74.
33. Fiorino G., Peyrin-Biroulet L., Naccarato P., et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012; 18 (6): 1042–7. DOI: https://doi.org/10.1002/ibd.21800
34. Wong S.Y., Dixon R., Martinez P.V., et al. Serologic response to messenger RNA Coronavirus disease 2019 vaccines in inflammatory bowel disease patients receiving biologic therapies. Gastroenterology. 2021; 161 (2): 715–8.e4. DOI: https://doi.org/10.1053/j.gastro.2021.04.025
35. Folegatti P.M., Ewer K.J., Aley P.K. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396: 467–78.